Departments of Pathology, Gachon University Gil Medical Center, Incheon, Korea
1Departments of Obstetrics and Gynecology, Gachon University Gil Medical Center, Incheon, Korea
© 2014 The Korean Society of Pathologists/The Korean Society for Cytopathology
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Case No. | Year | Age (yr) | Site | Side | Size (cm) | Symptom | History of VHL | VHL | Other |
---|---|---|---|---|---|---|---|---|---|
1[ |
1988 | 46 | MS | Lt | 3 | None | P (20 yr) | ReA, RCC,K/L/P cyst | Fimbrial adhesion |
2 | 1989 | 46 | BL | Lt | 3 | Mass | P (25 yr) | - | - |
3 | 1990 | 35 | BL | Rt | 5 | Pain | A | CbH, RCC,K/P cyst | - |
4[ |
1994 | 20 | BL | Rt | 4 | Nausea | A | CbH, RCC,ELST, K/P cyst | - |
5[ |
2005 | 32 | MS | NA | NA | NA | P | RCC | - |
6[ |
2005 | NA | MS | NA | NA | NA | A | - | Misdiagnosis (serous borderline tumor) |
7 | 2010 | 23 | MS | Rt | 3.5 | Pain | P (5 yr) | SpH | - |
8[ |
2012 | 52 | MS | Lt | 6 | Pain | N | - | Omental implant Misdiagnosis (malignant serous tumor) |
9[ |
2012 | 35 | BL | NA | 3.5 | None | P | - | - |
10[ |
2012 | 34 | MS | Rt | 5.5 | None | A | - | - |
11[ |
2012 | 24 | MS | Lt | 5 | None | A | - | - |
12[ |
2012 | 36 | MS | Bilat | Rt 5.2, Lt 3 | None | P | - | - |
13[ |
2012 | 47 | BL | Lt | 6.5 | None | P | CbH | Adhesion to rectum |
14[ |
2012 | 56 | PD | 6 | Pain | N | - | - | |
15 | Present case | 44 | MS | Lt | 3.9 | None | N | K/L cyst | Fallopian tube involvement |
Marker | Present case | 14 Reported cases | Positive rate (%) |
---|---|---|---|
CK7 | + | 10/10 | 100 |
Cam5.2 | + | 6/6 | 100 |
HMW-CK | + | 1/1 | 100 |
CK | ND | 5/5 | 100 |
CK19 | + | 1/1 | 100 |
CK20 | ND | 0/4 | 0 |
Ber-EP4 | ND | 3/3 | 100 |
EMA | + | 9/11 | 81.8 |
Vimentin | + | 8/9 | 88.9 |
CD10 | + | 9/10 | 90 |
α-Inhibin | – | 0/3 | 0 |
Calretinin | – | 3/8 | 37.5 |
AMACR | – | 0/11 | 0 |
HMB45 | – | 0/1 | 0 |
c-kit | – | 0/1 | 0 |
PAX2 | ND | 5/5 | 100 |
RCC marker | ND | 1/9 | 11.1 |
VHL40 | ND | 3/5 | 60 |
CA125 | ND | 5/7 | 71.4 |
WT-1 | ND | 4/7 | 57.1 |
HBME-1 | ND | 2/5 | 40 |
CEA | ND | 0/3 | 0 |
ER | ND | 0/2 | 0 |
PR | ND | 0/2 | 0 |
AR | ND | 2/7 | 28.6 |
VHL, von Hippel-Lindau disease; MS, mesosalpinx; Lt, left; P, previous history of VHL; ReA, retinal angioma; RCC, renal cell carcinoma; K/L/P, kidney/liver/pancreas; BL, broad ligament; Rt, right; A, VHL detected after the diagnosis of papillary cystadenoma; CbH, cerebellar hemangioblastoma; ELST, endolymphatic sac tumor; NA, not available; SpH, spinal cord hemangioblastoma; N, no previous history and no further detection of VHL after the diagnosis of papillary cystadenoma; Bilat, bilateral; PD, pouch of Douglas.
28.6CK, cytokeratin; HMW-CK, high-molecular weight cytokeratin; ND, not done; EMA, epithelial membrane antigen; AMACR, α-methylacyl coenzyme A racemase; HMB45, human melanoma black 45; RCC, renal cell carcinoma; VHL40, von Hippel-Lindau 40; CA125, cancer antigen 125; WT-1, Wilms tumour-1; CEA, carcinoembryonic antigen; ER, estrogen receptor; PR, progesterone receptor; AR, androgen receptor.